How Long Do Semaglutide Side Effects Last?

When Side Effects Persist: Seeking Help

If side effects continue beyond the initial adjustment period or become severe, seek medical advice. Mochi Health provides 1-on-1 provider support from licensed physicians who specialize in obesity medicine, ensuring you’re supported every step of the way.

Mochi Health Support Includes:

• Customized weight loss plans

• Medications delivered to your door

• Direct messaging with providers for immediate guidance

• Comprehensive follow-ups to adjust treatment plans as necessary

Semaglutide presents a promising solution for weight management, but understanding how to manage its side effects is vital to a successful treatment outcome.

If you’re considering semaglutide for weight loss, Mochi Health offers an accessible and supportive path to achieve your goals. With personalized programs, expert guidance, and continuous support, overcoming the challenges of obesity treatment is within reach.

Explore your options and check your eligibility for Mochi Health’s weight loss program today. Your journey to a healthier, more joyful life is just a step away.

References:

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

2. Baggio, L. L., & Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132(6), 2131–2157.. https://pubmed.ncbi.nlm.nih.gov/17498508/

3.  Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. doi: 10.1016/S2213-8587(17)30013-X. https://pubmed.ncbi.nlm.nih.gov/28110911/

4. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366. doi: 10.1016/S2213-8587(17)30085-2. https://pubmed.ncbi.nlm.nih.gov/28344112/

5. Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P. L., Wijayasinghe, N., & Norwood, P. (2018). Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of clinical endocrinology and metabolism, 103(6), 2291–2301. https://doi.org/10.1210/jc.2018-00070

6. Food and Drug Administration. Ozempic® (semaglutide) injection prescribing information, revised. 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf

7. Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of clinical medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.